Takeda's Ricardo Marek moves to new position

31 March 2017

Japan’s largest drugmaker Takeda Pharmaceuticals (TYO: 4502) says that Ricardo Marek has been appointed as the president of the Emerging Markets Business Unit (EM BU), based in Singapore, effective April 1, 2017.

In his new role he will lead all business operations across five geographic Areas that comprise EM BU – Asia Pacific (excluding Japan), China, Latin America, Middle East & Africa and Russia-CIS. Mr Marek will also serve as a corporate officer and member of Takeda’s Executive Team, and report to Christophe Weber, President and Chief Executive Officer of Takeda.

After joining Takeda in 2011, Mr Marek became president of Takeda Brazil in 2013. He then took-on additional, concurrent responsibilities, as area head of Latin America (LatAm) in 2014. He will be relocating from his home in São Paulo, Brazil, to Singapore and succeeds Giles Platford who has moved to Zurich as President of Europe and Canada, also effective April 1, 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK